332 related articles for article (PubMed ID: 25133306)
1. Is cerebrospinal fluid obtained for diagnostic purpose a good material for biomarker studies in amyotrophic lateral sclerosis?
Chełstowska B; Kuźma-Kozakiewicz M
Biomarkers; 2014 Nov; 19(7):571-7. PubMed ID: 25133306
[TBL] [Abstract][Full Text] [Related]
2. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Kawajiri M; Mogi M; Higaki N; Tateishi T; Ohyagi Y; Horiuchi M; Miki T; Kira JI
Acta Neurol Scand; 2009 May; 119(5):341-4. PubMed ID: 18798831
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential CSF biomarkers in ALS.
Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L
Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598
[TBL] [Abstract][Full Text] [Related]
4. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis.
Wilke C; Deuschle C; Rattay TW; Maetzler W; Synofzik M
Neurobiol Aging; 2015 Feb; 36(2):1072-4. PubMed ID: 25453560
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?
Mendonça DM; Martins SC; Higashi R; Muscara MN; Neto VM; Chimelli L; Martinez AM
Amyotroph Lateral Scler; 2011 Mar; 12(2):144-7. PubMed ID: 21198418
[TBL] [Abstract][Full Text] [Related]
6. Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis.
Gonçalves M; Tillack L; de Carvalho M; Pinto S; Conradt HS; Costa J
Clin Chim Acta; 2015 Jan; 438():342-9. PubMed ID: 25261856
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
[TBL] [Abstract][Full Text] [Related]
8. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis.
Tateishi T; Yamasaki R; Tanaka M; Matsushita T; Kikuchi H; Isobe N; Ohyagi Y; Kira J
J Neuroimmunol; 2010 May; 222(1-2):76-81. PubMed ID: 20381883
[TBL] [Abstract][Full Text] [Related]
9. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis.
Paladino P; Valentino F; Piccoli T; Piccoli F; La Bella V
Eur J Neurol; 2009 Feb; 16(2):257-61. PubMed ID: 19138331
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry.
Blasco H; Corcia P; Pradat PF; Bocca C; Gordon PH; Veyrat-Durebex C; Mavel S; Nadal-Desbarats L; Moreau C; Devos D; Andres CR; Emond P
J Proteome Res; 2013 Aug; 12(8):3746-54. PubMed ID: 23859630
[TBL] [Abstract][Full Text] [Related]
12. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
[TBL] [Abstract][Full Text] [Related]
13. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
[TBL] [Abstract][Full Text] [Related]
14. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis.
Tortelli R; Copetti M; Ruggieri M; Cortese R; Capozzo R; Leo A; D'Errico E; Mastrapasqua M; Zoccolella S; Pellegrini F; Simone IL; Logroscino G
Eur J Neurol; 2015 Jan; 22(1):215-8. PubMed ID: 24750431
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cerebral spinal fluid pH and HCO3- with disease progression in ALS.
Morimoto N; Deguchi K; Sato K; Yunoki T; Deguchi S; Ohta Y; Kurata T; Takao Y; Ikeda Y; Matsuura T; Abe K
J Neurol Sci; 2011 Aug; 307(1-2):74-8. PubMed ID: 21632065
[TBL] [Abstract][Full Text] [Related]
17. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Jiménez-Jiménez FJ; Hernánz A; Medina-Acebrón S; de Bustos F; Zurdo JM; Alonso H; Puertas I; Barcenilla B; Sayed Y; Cabrera-Valdivia F
Acta Neurol Scand; 2005 Feb; 111(2):114-7. PubMed ID: 15644071
[TBL] [Abstract][Full Text] [Related]
18. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
Collins MA; An J; Hood BL; Conrads TP; Bowser RP
J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
[TBL] [Abstract][Full Text] [Related]
19. Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis.
Watanabe S; Kimura T; Suenaga K; Wada S; Tsuda K; Kasama S; Takaoka T; Kajiyama K; Takeda M; Yoshikawa H
J Neurol Sci; 2009 Oct; 285(1-2):146-8. PubMed ID: 19595376
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Zheng Y; Gao L; Wang D; Zang D
Acta Neurol Scand; 2017 Aug; 136(2):145-150. PubMed ID: 27804118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
